HHS announces Medicare premium increase for Aduhelm will be adjusted in 2023
Click Here to Manage Email Alerts
HHS announced that Medicare Part B premiums paid in 2022 should be lowered in 2023 to account for an overestimate in costs related to inclusion of Aduhelm within the Medicare program for reimbursement.
According to an HHS release, legal and operational hurdles prevented adjustments in Medicare premiums this year, prompting reductions in costs attributable to Aduhelm (aducanumab, Biogen) into Medicare premiums in 2023 to lower Part B premiums paid by Medicare beneficiaries.
The decision to lower premium payments arose after HHS received a report from CMS, which concluded that cost savings from lower-than-expected Medicare Part B spending on Aduhelm can be passed along to beneficiaries by lowering the 2023 Part B premium.
“We had hoped to achieve this sooner, but CMS explains that the options to accomplish this would not be feasible,” HHS Secretary Xavier Becerra said in the release. “CMS and HHS are committed to lowering health care costs — so we look forward to seeing this Medicare premium adjustment across the finish line to ensure seniors get their cost-savings in 2023.”